$SLXN News
Last published 1d ago
- 1d agoSLXNTrading halt: Silexion Therapeutics Corp OS (SLXN), News pendingNasdaq Trading HaltsHalted 2026-11-10 19:50:00.000 ET, resumption quote none, resumption trade none.
- 2d agoSLXNSilexion Therapeutics Announces 1-for-24 Reverse Share SplitGlobeNewswireTrading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its market
- 2d agoSLXNSilexion Therapeutics Announces 1-for-24 Reverse Share SplitGlobeNewswireTrading on a split-adjusted basis will begin at market open on November 11, 2026.
- 1mo agoSLXNSilexion Therapeutics Corp 2026 Extraordinary General Meeting - SILEXION THERAPEUTICS CORPEarnings Call TranscriptsLadies and gentlemen, I am Mitchell Shervan, Chief Scientific and Development Officer of Selexion Therapeutics Corporation and Chairman of this meeting. I hereby call this reconvened extraordinary general meeting of Sele
- 1mo agoSLXNSilexion Therapeutics Corp 2026 Extraordinary General Meeting - SILEXION THERAPEUTICS CORPEarnings Call TranscriptsLadies and gentlemen, I am Mitchell Shervan, Chief Scientific and Development Officer of Selexion Therapeutics Corporation and Chairman of this meeting. I hereby call this reconvened extraordinary general meeting of Sele
- 2mo agoSLXNSilexion Therapeutics to Participate in September 2026 Industry and Investor ConferencesGlobeNewswireGrand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA
- 2mo agoSLXNSilexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireSuccessfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026
- 3mo agoSLXNSilexion Therapeutics Announces Pricing of $2.5 Million Public OfferingGlobeNewswireGRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotechnology company pioneering
- 3mo agoSLXNSilexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven CancersGlobeNewswireNew preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune "death receptor," and statistically significant downregulation of HLA-G, an
- 3mo agoSLXNSilexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical CenterGlobeNewswireSuccessful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center ("TASMC" or "Ichilov"), one of Israel’s largest and most prominent academic medical centers, clears the
- 4mo agoSLXNSilexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerGlobeNewswireCTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate
- 4mo agoSLXNSilexion Therapeutics to Attend BIO International Convention 2026GlobeNewswireGrand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,
- 5mo agoSLXNSilexion Therapeutics Announces 1-for-10 Reverse Share SplitGlobeNewswireGrand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for
- 5mo agoSLXNSilexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireIsraeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany through the EU
- 6mo agoSLXNSilexion Therapeutics Announces Exercise of Warrants for $1 Million Gross ProceedsGlobeNewswireGrand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for
- 6mo agoSLXNSilexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic CancerGlobeNewswireGrand Cayman, Cayman Islands, May 14, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference
- 6mo agoSLXNSilexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical CenterGlobeNewswireSilexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of
- 6mo agoSLXNSilexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic CancerGlobeNewswireGrand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA
- 7mo agoSLXNSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerGlobeNewswireSignificant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent
- 8mo agoSLXNSilexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General MeetingGlobeNewswireGrand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the
- 9mo agoSLXNSilexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics SummitGlobeNewswireGrand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage, oncology-focused biotechnology company, today announced that Company
- 11mo agoSLXNSilexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic CancerGlobeNewswireRegulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies, positive German regulatory
- 11mo agoSLXNSilexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic CancerGlobeNewswirePositive feedback reinforces Silexion's trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in
- 11mo agoSLXNSilexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity ConferenceGlobeNewswireGrand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage, oncology-focused biotechnology company, today announced that Company
- 11mo agoSLXNSilexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic CancerGlobeNewswireSuccessful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on track to initiate
- 12mo agoSLXNSilexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireContinued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell lines, highlighting
- 1y agoSLXNSilexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric CancerGlobeNewswireNew data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer
- 1y agoSLXNSilexion Therapeutics Regains Compliance with Nasdaq Listing RequirementsGlobeNewswireGRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp.
- 1y agoSLXNSilexion Therapeutics Announces Pricing of $6.0 Million Public OfferingGlobeNewswireGrand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for
- 1y agoSLXNSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationGlobeNewswireNew Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further Validation of the Systemic
- 1y agoSLXNSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204GlobeNewswireStrategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 Following Q4 2025 and
- 1y agoSLXNSilexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceGlobeNewswireGrand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)
- 1y agoSLXNSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireGRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA
- 1y agoSLXNSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsGlobeNewswireCayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) therapies for
- 1y agoSLXNSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationGlobeNewswireGrand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)
- 1y agoSLXNSilexion Therapeutics Announces 1-for-15 Reverse Share SplitGlobeNewswireGrand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)
- 1y agoSLXNSilexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung CancersGlobeNewswireGRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference
- 1y agoSLXNSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung CancerGlobeNewswireGRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) therapies for
- 1y agoSLXNSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireGRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) therapies for
- 1y agoSLXNSilexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing ActivitiesGlobeNewswireGrand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)
- 1y agoSLXNSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataGlobeNewswireGrand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)
- 1y agoSLXNSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer ConferenceGlobeNewswireGrand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for
- 1y agoSLXNSilexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireGrand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA
- 1y agoSLXNPESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer TreatmentBusiness WireSilexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative Therapy; Wall Street Maintains Buy Rating and $9 Price Target
- 1y agoSLXNSilexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer ModelsGlobeNewswireGrand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA
- 1y agoSLXNPESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be TransformationalBusiness WireSilexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time.
- 1y agoSLXNSilexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204GlobeNewswireGrand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA
- 1y agoSLXNSilexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross ProceedsGlobeNewswireCayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,
- 1y agoSLXNPESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology MarketBusiness WireSilexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price Target as Company Advances
- 1y agoSLXNSilexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer ModelsGlobeNewswireCayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,